Publication

ISPOR-Eu •
17 November, 2024 •
•

Loncastuximab tesirine versus glofitamab for the treatment of relapsed/refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy: a matching-adjusted indirect comparison

Koo Wilson, Francesca Chiodi, Abby Paine, Zalmai Hakimi, Silvia Mappa, Victoria Crowe, Tom Macmillan, Daniel Eriksson, Georg Lenz

Available materials

Poster

Publication

ISPOR-Eu •
17 November, 2024 •
•

Real-world survey on healthcare resource utilisation and physician-reported burden in patients with primary Immune Complex Membranoproliferative Glomerulonephritis

Carly Rich, Dima Decker, Lucía Quintana-Gallardo, James Jackson, Sarah Clayton, Kristie Fitzmaurice, Mollie Lowe, Katie Gordon, Mingyi Huang

Available materials

Poster

Publication

ESPN •
17 October, 2025 •
•

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary IC-MPGN: Phase 3 VALIANT study results

Christoph Licht, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Nayoa Fujita, Larry A Greenbaum, Antonio Mastrangelo, Nabil Melhem, Nicole CAJ Van de Kar, Marina Vivarelli, Dean Wallace, Virginia Taliadouros, Johan Szamosi, Katie Gordon, Zhongshen Wang, Carla M Nester

Publication

ESPN •
16 October, 2025 •
•

Pegcetacoplan for paediatric patients with C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Real-world survey on treatment pathways and patterns for patients with primary Immune Complex Membranoproliferative Glomerulonephritis

Loncastuximab tesirine versus glofitamab for the treatment of relapsed/refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy: a matching-adjusted indirect comparison

Real-world survey on healthcare resource utilisation and physician-reported burden in patients with primary Immune Complex Membranoproliferative Glomerulonephritis

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary IC-MPGN: Phase 3 VALIANT study results

Pegcetacoplan for paediatric patients with C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Pegcetacoplan for post-transplant patients with complement 3 glomerulopathy or primary (idiopathic) immune-complex membranoproliferative glomerulonephritis: an analysis of the phase 2 NOBLE and phase 3 VALIANT trials

Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex Membranoproliferative Glomerulonephritis

Real-world survey on treatment pathways and patterns for patients with primary Immune Complex Membranoproliferative Glomerulonephritis

Loncastuximab tesirine versus glofitamab for the treatment of relapsed/refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy: a matching-adjusted indirect comparison

Real-world survey on healthcare resource utilisation and physician-reported burden in patients with primary Immune Complex Membranoproliferative Glomerulonephritis

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary ​ IC-MPGN: Phase 3 VALIANT study results

Pegcetacoplan for paediatric patients with​ C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Pegcetacoplan for post-transplant patients with complement 3 glomerulopathy or primary (idiopathic) immune-complex membranoproliferative glomerulonephritis: an analysis of the phase 2 NOBLE and phase 3 VALIANT trials

Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex Membranoproliferative Glomerulonephritis

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary IC-MPGN: Phase 3 VALIANT study results

Pegcetacoplan for paediatric patients with C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study